Garde Capital Inc. Reduces Position in Johnson & Johnson (NYSE:JNJ)

Garde Capital Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 3.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,009 shares of the company’s stock after selling 75 shares during the period. Garde Capital Inc.’s holdings in Johnson & Johnson were worth $326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of JNJ. ERn Financial LLC raised its position in shares of Johnson & Johnson by 2.9% in the second quarter. ERn Financial LLC now owns 7,221 shares of the company’s stock worth $1,055,000 after acquiring an additional 202 shares during the period. Mcdonald Partners LLC increased its position in shares of Johnson & Johnson by 2.3% in the second quarter. Mcdonald Partners LLC now owns 26,481 shares of the company’s stock valued at $3,871,000 after buying an additional 585 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. raised its stake in shares of Johnson & Johnson by 16.1% during the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 26,377 shares of the company’s stock worth $3,855,000 after buying an additional 3,666 shares during the period. Home Federal Bank of Tennessee grew its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Home Federal Bank of Tennessee now owns 17,608 shares of the company’s stock valued at $2,574,000 after acquiring an additional 119 shares during the period. Finally, Hunter Perkins Capital Management LLC increased its holdings in Johnson & Johnson by 16.6% in the 2nd quarter. Hunter Perkins Capital Management LLC now owns 101,655 shares of the company’s stock worth $14,858,000 after acquiring an additional 14,456 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on JNJ. Bank of America reiterated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research report on Tuesday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $146.23 on Friday. The company’s 50 day moving average is $157.01 and its two-hundred day moving average is $156.28. The firm has a market cap of $352.07 billion, a PE ratio of 21.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.66 EPS. On average, research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.